Cheetah Medical, a Massachusetts based leader in non-invasive hemodynamic monitoring, announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock. Initial results of this study were previously presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress in Brussels, and the full study is now published online in the Journal of Critical Care.

The results, authored by Drs. Heath Latham and Steven Q. Simpson from the University of Kansas Health System, demonstrate strong clinical value for fluid resuscitation strategies using Stroke Volume and dynamic assessments, and guided by Cheetah Medical technology:

– ICU Length of Stay: reduced by 2.89 days
– Risk of Mechanical Ventilation: reduced by 51%
– Initiation of Acute Dialysis Therapy: reduced by 13.25%
– Pressor Use: reduced by 32.78 hours
– Fluid Balance: reduced by 3.59L

Sepsis is the most expensive inpatient cost to hospitals in the United States, costing an average of $25,000 – $50,0001 per episode. The positive clinical outcomes from this study, in turn, can enhance patient safety and result in a significant reduction of these costs.

Major societies, including the Surviving Sepsis Campaign and National Quality Forum, have recently updated their sepsis management guidelines to recommend dynamic assessment of fluid responsiveness. Research shows that serious complications can result from giving a patient too little or too much IV fluids, which can lead to increased length of stay, increased mortality and increased complications.

“This study builds on the broad outcome data in the surgical literature showing the value of using dynamic assessments to guide fluid management. It is exciting to see the role that Cheetah can play in these strategies to improve care in sepsis patients.” said Dr. Doug Hansell, Chief physician Executive at Cheetah Medical.

Dr. Heath Latham from the University of Kansas Health System, comments, “We embarked on this study with the hypothesis that actively managing patients’ fluids was associated with improved clinical outcomes. The study demonstrated positive patient outcomes from actively monitoring resuscitation by optimizing stroke volume, that can be translated to significant cost savings to the hospitals caring for these very critical patients. University of Kansas Health System realized an associated savings of about $14 million for 1,000 sepsis patients that were monitored by Cheetah technology.”

Details about the factors making up these financial savings can be found at www.cheetahmedical.com.

About Cheetah Medical
Cheetah Medical is the pioneer and leading global provider of 100% noninvasive hemodynamic monitoring technologies which are designed for use in critical care, operating room, general care floor, and emergency department settings. The CHEETAH NICOM™ and STARLING™ SV technologies use a proprietary algorithm to provide accurate and precise data, enabling clinicians to quickly see a patient’s full hemodynamic profile. Medical professionals use this information to assess patients’ unique volume requirements, guide volume management decisions and maintain adequate organ perfusion. Cheetah Medical technologies are designed to enable more confident, informed therapy decisions that support clinical goals of improving patient outcomes and driving economic efficiencies.

1 Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 2012; 10(6) 701-706.

Latest news

OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023

OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]

MVM invests in Neurolens
September 12, 2022

Neurolens, a company commercializing innovative solutions to optimize vision, today announced completion of a $67 million financing. The financing was led by […]

MDxHealth acquires Oncotype DX GPS test
August 2, 2022

MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced it has entered into an […]

Nalu announces new CEO
July 14, 2022

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today […]

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]